Nectar Lifesciences share news, announcements and annual reports
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Nectar Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2005
Last close ₹10.20down ₹0.13 (1.26%)BSE ₹10.29
Share price at the NSE close on 30 Oct 2026. Previous close ₹10.33.
30 Oct: open ₹10.43, high ₹10.43, low ₹9.82
52-week range of traded prices to 30 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹198 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 95,05079.2% delivered
Nectar Lifesciences share news and announcements
590 announcements, routine notices left out, newest first. Page 5 of 12.
Jul 2022
Jun 2022
7 Jun · Related Party Transaction
May 2022
30 May · General updates
30 May · Results
Apr 2022
8 Apr · Annual Disclosure
Feb 2022
14 Feb · Results
Dec 2021
6 Dec · Related Party Transactions
Nov 2021
13 Nov · Results
Sep 2021
21 Sep · Meeting
Aug 2021
14 Aug · Results
Jul 2021
26 Jul · Related Party Transactions
23 Jul · Board meeting
23 Jul · Results
Jun 2021
29 Jun · Results
28 Jun · Legal
Exchange has sought clarification from Nectar Lifesciences Limited with respect to announcement dated 25-Jun-2021, regarding Resignation of Mr Maj. Gen. (Retd.) Dr. Ajit Singh Dhillon as Independent Director of the company w.e.f. Jun 24, 2021. On basis of above the Company is required to clarify following: 1. No other material reasons other than provided.The response of the Company is awaited.
Apr 2021
27 Apr · Legal
The exchange asked on 23 Apr 2021
12 Apr · Annual Disclosure
Feb 2021
13 Feb · Results
1 Feb · Updates
Jan 2021